دورية أكاديمية
أعرض في EDS

Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways.

التفاصيل البيبلوغرافية
العنوان: Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways.
المؤلفون: Williams MM; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Hafeez SA; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Christenson JL; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., O'Neill KI; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Hammond NG; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Richer JK; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
المصدر: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2021 Nov 02; Vol. 14 (11). Date of Electronic Publication: 2021 Nov 02.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c2004-
مستخلص: Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence demonstrates that TNBC metastases are more immune suppressed than primary tumors, suggesting that combination or additional immunotherapy strategies may be required to activate an anti-tumor immune attack at metastatic sites. To identify other immune suppressive mechanisms utilized by mTNBC, our group and others manipulated oncogenic epithelial-to-mesenchymal transition (EMT) programs in TNBC models to reveal differences between this breast cancer subtype and its more epithelial counterpart. This review will discuss how EMT modulation revealed several mechanisms, including tumor cell metabolism, cytokine milieu and secretion of additional immune modulators, by which mTNBC cells may suppress both the innate and adaptive anti-tumor immune responses. Many of these pathways/proteins are under preclinical or clinical investigation as therapeutic targets in mTNBC and other advanced cancers to enhance their response to chemotherapy and/or checkpoint inhibitors.
References: Calcif Tissue Int. 2003 Mar;72(3):197-205. (PMID: 12469249)
Expert Opin Ther Pat. 2019 Jan;29(1):11-23. (PMID: 30526149)
J Clin Invest. 2015 Jul 1;125(7):2592-608. (PMID: 26011642)
J Cell Commun Signal. 2009 Dec;3(3-4):311-22. (PMID: 19798593)
Nat Med. 2011 Oct 23;17(11):1514-20. (PMID: 22019887)
Crit Rev Oral Biol Med. 2000;11(3):279-303. (PMID: 11021631)
Nat Commun. 2018 Jul 27;9(1):2951. (PMID: 30054470)
Oncogene. 2017 Aug;36(31):4457-4468. (PMID: 28368410)
Int J Mol Med. 2017 Aug;40(2):411-417. (PMID: 28627599)
Cancer Res. 2014 Sep 1;74(17):4706-19. (PMID: 25035397)
Nat Med. 2007 Jan;13(1):62-9. (PMID: 17159986)
Oncologist. 1999;4(2):106-11. (PMID: 10337380)
Cancer Res. 2013 Aug 1;73(15):4885-97. (PMID: 23737486)
Dig Dis Sci. 1996 Jul;41(7):1468-74. (PMID: 8689926)
Mol Carcinog. 2013 Oct;52(10):824-34. (PMID: 22593043)
Ther Adv Med Oncol. 2019 Jun 21;11:1758835919854238. (PMID: 31258629)
Annu Rev Pharmacol Toxicol. 2001;41:723-49. (PMID: 11264474)
N Engl J Med. 2018 Nov 29;379(22):2108-2121. (PMID: 30345906)
Cancer Res. 2015 Jul 15;75(14):2775-87. (PMID: 25977333)
Cell Transplant. 2010;19(4):443-51. (PMID: 20021735)
Nat Commun. 2020 Dec 2;11(1):6175. (PMID: 33268821)
Cancer Res. 2015 Nov 1;75(21):4651-64. (PMID: 26363006)
Front Immunol. 2020 Jun 16;11:1185. (PMID: 32612606)
J Exp Med. 2001 Mar 19;193(6):727-40. (PMID: 11257139)
Cell Death Dis. 2014 Mar 20;5:e1135. (PMID: 24651438)
Exp Dermatol. 2009 Sep;18(9):750-9. (PMID: 19558497)
Metabolites. 2021 Sep 15;11(9):. (PMID: 34564442)
J Immunol. 2008 Aug 1;181(3):1887-97. (PMID: 18641326)
Cancer Res. 2020 Jun 15;80(12):2628-2638. (PMID: 32312837)
J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34667078)
BMC Cancer. 2015 Aug 15;15:590. (PMID: 26275425)
J Clin Oncol. 2009 Dec 10;27(35):5911-8. (PMID: 19805669)
Cell Death Differ. 2002 Oct;9(10):1069-77. (PMID: 12232795)
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):173-7. (PMID: 14734466)
Genes Dev. 2013 Oct 15;27(20):2192-206. (PMID: 24142872)
JCI Insight. 2020 Jun 4;5(11):. (PMID: 32369450)
FASEB J. 2004 Apr;18(6):765-7. (PMID: 14977878)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935)
Clin Immunol. 2021 Apr;225:108679. (PMID: 33485895)
Oncol Rep. 2009 Apr;21(4):977-81. (PMID: 19287996)
Am J Transl Res. 2015 Apr 15;7(4):723-32. (PMID: 26064440)
Oncologist. 2017 Nov;22(11):1316-1324. (PMID: 28701569)
Nat Commun. 2014 Oct 28;5:5241. (PMID: 25348003)
BMC Cancer. 2019 Dec 18;19(1):1230. (PMID: 31849319)
Trends Cardiovasc Med. 1995 May-Jun;5(3):88-95. (PMID: 21232243)
Am J Respir Crit Care Med. 2016 Jan 15;193(2):131-42. (PMID: 26372680)
Oncogene. 2010 Sep 30;29(39):5346-58. (PMID: 20661219)
Oncogene. 2021 Jan;40(3):475-491. (PMID: 33235291)
Clin Cancer Res. 2013 Oct 15;19(20):5626-35. (PMID: 23983257)
Nature. 2008 May 1;453(7191):65-71. (PMID: 18362915)
Cancer Res. 2001 May 1;61(9):3689-97. (PMID: 11325840)
Br J Cancer. 2020 Jan;122(1):30-44. (PMID: 31819194)
J Exp Med. 2000 Oct 2;192(7):1015-26. (PMID: 11015442)
Nature. 2011 Oct 05;478(7368):197-203. (PMID: 21976023)
Molecules. 2019 Nov 28;24(23):. (PMID: 31795096)
Biochem Pharmacol. 1995 May 17;49(10):1435-42. (PMID: 7539265)
BMC Cancer. 2021 Aug 6;21(1):899. (PMID: 34362344)
J Proteomics. 2019 Sep 30;208:103469. (PMID: 31374364)
Clin Cancer Res. 2016 Feb 1;22(3):609-20. (PMID: 26420858)
Clin Exp Metastasis. 1999 Mar;17(2):163-70. (PMID: 10411109)
Breast Cancer Res Treat. 2010 Aug;123(1):39-49. (PMID: 19898981)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
J Biol Chem. 1997 Mar 28;272(13):8137-40. (PMID: 9079626)
J Vis Exp. 2016 Dec 26;(118):. (PMID: 28060292)
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52. (PMID: 20080644)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Immunol Res. 2013 Dec;57(1-3):99-105. (PMID: 24222276)
Clin Cancer Res. 2020 Jun 1;26(11):2515-2523. (PMID: 32071118)
Breast Cancer Res Treat. 2010 Sep;123(2):397-404. (PMID: 19949854)
Br J Cancer. 2015 Feb 17;112(4):729-38. (PMID: 25625274)
Cancer Immunol Res. 2014 Oct;2(10):949-61. (PMID: 25116755)
Nat Commun. 2020 Jan 24;11(1):515. (PMID: 31980601)
Breast Cancer Res. 2011 Apr 18;13(2):R45. (PMID: 21501518)
Eur J Biochem. 1998 Jan 15;251(1-2):504-9. (PMID: 9492324)
Vet Pathol. 2015 Sep;52(5):827-41. (PMID: 26021553)
J Immunol. 2012 Jan 1;188(1):198-205. (PMID: 22116822)
Oncol Lett. 2015 Nov;10(5):2974-2980. (PMID: 26722274)
Cancer Res. 2007 Mar 15;67(6):2649-56. (PMID: 17363585)
Cancer Cell. 2014 May 12;25(5):605-20. (PMID: 24823638)
Sci Rep. 2016 May 20;6:26299. (PMID: 27198666)
J Biol Chem. 1993 Dec 5;268(34):25803-10. (PMID: 8245017)
Am Heart J. 1992 Jul;124(1):13-8. (PMID: 1615795)
Ann Oncol. 2019 Aug 1;30(8):1381-1392. (PMID: 31114846)
Cancer Res. 2017 Aug 1;77(15):3982-3989. (PMID: 28428275)
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9640-E9648. (PMID: 30242135)
Oncoimmunology. 2017 Jan 23;6(1):e1263412. (PMID: 28197390)
Sci Rep. 2021 Mar 16;11(1):6035. (PMID: 33727591)
J Pathol. 2012 May;227(1):106-17. (PMID: 22081431)
Horm Cancer. 2010 Dec;1(6):306-19. (PMID: 21761362)
NPJ Breast Cancer. 2021 May 27;7(1):64. (PMID: 34045467)
Nat Commun. 2018 Jan 2;9(1):21. (PMID: 29295986)
Int J Cancer. 2012 Jul 15;131(2):377-86. (PMID: 21866546)
Semin Immunopathol. 2019 Jan;41(1):41-48. (PMID: 30203227)
Neoplasma. 2014;61(6):680-9. (PMID: 25150313)
Sci Rep. 2020 Jan 29;10(1):1451. (PMID: 31996744)
Hepatology. 2004 Dec;40(6):1333-41. (PMID: 15565657)
Mol Cell Proteomics. 2009 Jun;8(6):1436-49. (PMID: 19321434)
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44. (PMID: 23483055)
Mol Cancer Res. 2019 Jan;17(1):30-41. (PMID: 30213797)
Clin Cancer Res. 2020 May 1;26(9):2176-2187. (PMID: 31953314)
BMC Cancer. 2013 Nov 01;13:516. (PMID: 24180625)
Front Oncol. 2021 Mar 10;11:645698. (PMID: 33777805)
Cancer Immunol Res. 2014 Aug;2(8):765-76. (PMID: 25005824)
Invest New Drugs. 2021 Aug;39(4):1057-1071. (PMID: 33624233)
Nat Rev Cancer. 2017 Dec;17(12):709-724. (PMID: 29059149)
Clin Exp Metastasis. 2005;22(1):47-59. (PMID: 16132578)
N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385)
Mol Ther Oncolytics. 2020 Mar 30;17:153-168. (PMID: 32346606)
Am J Pathol. 2003 Nov;163(5):2113-26. (PMID: 14578209)
Anticancer Res. 2008 Nov-Dec;28(6B):4105-10. (PMID: 19192668)
Nat Cell Biol. 2019 Sep;21(9):1113-1126. (PMID: 31451770)
Oncoimmunology. 2016 Jul 11;5(8):e1208875. (PMID: 27622077)
Breast Cancer. 1999 Oct 25;6(4):301-304. (PMID: 11091734)
J Immunol. 2010 Sep 15;185(6):3190-8. (PMID: 20720200)
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6. (PMID: 23776241)
Nature. 2018 Feb 15;554(7692):378-381. (PMID: 29414946)
Cancer Res. 2009 Mar 1;69(5):2133-40. (PMID: 19223554)
Tumour Biol. 2014 Jan;35(1):277-86. (PMID: 23918300)
Cancer Res. 2006 Dec 1;66(23):11238-46. (PMID: 17114237)
J Thorac Dis. 2013 Aug;5(4):385-92. (PMID: 23991292)
Anticancer Res. 2015 Feb;35(2):865-74. (PMID: 25667468)
Cancer Immunol Res. 2020 Oct;8(10):1273-1286. (PMID: 32847938)
Cancer Res. 2016 Aug 1;76(15):4372-82. (PMID: 27221704)
Clin Cancer Res. 2020 Feb 1;26(3):657-668. (PMID: 31611282)
Oncogene. 2015 Dec 3;34(49):5997-6006. (PMID: 25746005)
Front Oncol. 2021 Mar 26;11:593337. (PMID: 33842308)
Mol Pharmacol. 2016 Nov;90(5):674-688. (PMID: 27573671)
Clin Exp Metastasis. 2020 Jun;37(3):401-412. (PMID: 32279122)
Oncol Res. 2013;20(10):473-82. (PMID: 24308158)
Br J Cancer. 2011 Oct 11;105(8):1203-9. (PMID: 21934681)
Int J Mol Sci. 2020 Dec 30;22(1):. (PMID: 33396647)
Cancer Res. 1997 Jul 1;57(13):2602-5. (PMID: 9205063)
Clin Cancer Res. 2015 May 15;21(10):2305-14. (PMID: 25688159)
In Vitro Cell Dev Biol Anim. 2019 Dec;55(10):838-853. (PMID: 31482369)
Cancer Immunol Res. 2021 Feb;9(2):214-226. (PMID: 33303575)
Folia Microbiol (Praha). 1985;30(4):373-80. (PMID: 4029818)
Gene. 1995 Feb 14;153(2):147-54. (PMID: 7875581)
Mol Cancer Res. 2019 Jan;17(1):131-139. (PMID: 30143553)
Cancer Lett. 2017 Jun 28;396:117-129. (PMID: 28323032)
J Cell Mol Med. 2018 Nov;22(11):5311-5321. (PMID: 30216645)
Cancer Res. 2015 Feb 1;75(3):487-96. (PMID: 25511377)
Ann Oncol. 2007 Feb;18(2):226-32. (PMID: 17116643)
Pediatrics. 1994 Jan;93(1):1-11. (PMID: 8265301)
Ann Oncol. 2018 Apr 1;29(4):1056-1062. (PMID: 29145561)
J Immunother Cancer. 2019 Oct 18;7(1):265. (PMID: 31627744)
Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938. (PMID: 28469468)
J Immunol. 2009 Jul 15;183(2):1022-31. (PMID: 19564344)
Endocr Relat Cancer. 2013 Oct 14;20(6):777-83. (PMID: 24016870)
Oncol Res. 2019 Jun 21;27(6):643-651. (PMID: 30764900)
Am J Physiol Renal Physiol. 2006 Mar;290(3):F563-71. (PMID: 16461755)
J Leukoc Biol. 1996 Oct;60(4):540-5. (PMID: 8864140)
Front Mol Biosci. 2020 Nov 24;7:565383. (PMID: 33324676)
Oncogenesis. 2018 Mar 29;7(3):32. (PMID: 29593211)
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248. (PMID: 29367423)
Nat Commun. 2016 Jul 06;7:12150. (PMID: 27381735)
Onco Targets Ther. 2017 Aug 18;10:4121-4127. (PMID: 28860821)
Cell Cycle. 2011 Dec 1;10(23):4149-61. (PMID: 22101269)
Biochem Biophys Res Commun. 2005 Dec 16;338(2):890-6. (PMID: 16246303)
J Exp Med. 2002 Aug 19;196(4):447-57. (PMID: 12186837)
Cancer Res. 2002 Mar 15;62(6):1613-8. (PMID: 11912130)
Cancer Discov. 2021 May;11(5):1286-1305. (PMID: 33328216)
Anticancer Res. 2018 Jun;38(6):3357-3366. (PMID: 29848684)
Nat Commun. 2018 Feb 5;9(1):503. (PMID: 29403003)
Cell Death Dis. 2020 Mar 23;11(3):202. (PMID: 32205841)
Cancer Res. 2004 Oct 1;64(19):7022-9. (PMID: 15466195)
Biochem Soc Trans. 2009 Apr;37(Pt 2):408-12. (PMID: 19290871)
Cancer Res. 2021 Feb 1;81(3):732-746. (PMID: 33184106)
Blood. 2014 Nov 13;124(20):3141-50. (PMID: 25277122)
Oncogene. 2020 Sep;39(39):6139-6156. (PMID: 32839493)
Mol Cancer Ther. 2009 May;8(5):1055-66. (PMID: 19435871)
J Med Chem. 2011 Aug 11;54(15):5320-34. (PMID: 21726069)
Cancer Res. 1992 Mar 15;52(6):1399-405. (PMID: 1540948)
Clin Cancer Res. 2009 Feb 1;15(3):778-87. (PMID: 19188147)
Clin Cancer Res. 2021 Oct 6;:. (PMID: 34615719)
J Clin Invest. 2021 Oct 15;131(20):. (PMID: 34520398)
J Immunol. 2018 Jul 15;201(2):782-791. (PMID: 29802128)
Clin Cancer Res. 2003 Oct 1;9(12):4423-34. (PMID: 14555515)
Br J Cancer. 2010 Oct 26;103(9):1331-4. (PMID: 20877352)
Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. (PMID: 29339440)
Cancer Sci. 2015 Aug;106(8):1023-32. (PMID: 26041409)
Cancer Epidemiol. 2013 Dec;37(6):985-92. (PMID: 24012693)
Breast Cancer Res Treat. 2003 Jul;80(1):15-21. (PMID: 12889595)
Sci Rep. 2018 Jun 21;8(1):9427. (PMID: 29930294)
Breast J. 2006 Sep-Oct;12(5):475-80. (PMID: 16958969)
Cancer Res. 2015 Mar 15;75(6):963-73. (PMID: 25600648)
Front Immunol. 2018 May 15;9:776. (PMID: 29867922)
Proc Assoc Am Physicians. 1998 Jul-Aug;110(4):351-60. (PMID: 9686683)
Clin Immunol. 2019 Apr;201:48-54. (PMID: 30817999)
Am J Transl Res. 2017 Aug 15;9(8):3749-3757. (PMID: 28861166)
Ann N Y Acad Sci. 2010 Jan;1183:25-37. (PMID: 20146706)
معلومات مُعتمدة: T32 CA190216 United States CA NCI NIH HHS; F32CA239436 United States NH NIH HHS; T32CA190216 United States NH NIH HHS; W81XWH-15-1-0039 United States Department of Defense; W81XWH-19-BCRP-EA United States Department of Defense; F32 CA239436 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: epithelial-to-mesenchymal transition; immune suppression; immunotherapy; metastasis; triple negative breast cancer
تواريخ الأحداث: Date Created: 20211127 Latest Revision: 20211201
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8622696
DOI: 10.3390/ph14111122
PMID: 34832904
قاعدة البيانات: MEDLINE
الوصف
تدمد:1424-8247
DOI:10.3390/ph14111122